Long-term treatment with Boehringer Ingelheim‘s Ofev (nintedanib) improved the lung function and reduced the flare-ups of people with idiopathic pulmonary fibrosis, results of a Phase 2 clinical trial and its extension show.
The study, “Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension,” appeared in the journal Thorax.
IPF is a progressive lung disease with a median survival rate of only three years after diagnosis. The Phase 2 TOMORROW trial (NCT00514683) evaluated Ofev’s safety and effectiveness in two periods.Period 1 covered 52 weeks. The 428 patients in the randomized, placebo-controlled study received one of four doses of Ofev.
